T he use of low-dose dopamine to prevent or even treat renal dysfunction has become a widely accepted clinical practice. Indeed, some management protocols even include routine orders for "renal dose" dopamine. Animal experiments and human trials have provided extensive documentation of the effects of dopamine on renal hemodynamics (e.g., increased renal blood flow, short-term increases in glomerular filtration rate) and on urine output (1) (2) (3) . However, there is no evidence that these effects are beneficial in patients with, or at risk for, renal dysfunction (4) . In a previous systematic review of 19 studies, benefit was defined as a positive effect on renal function persisting after the intervention, a decrease in mortality, or a decrease in requirement for hemodialysis (4) . Among these trials, only 2 were positive-both were methodologically inferior-and the remaining 17 studies, collectively enrolling more than 700 patients, were all negative. Unfortunately, no single study was sufficiently powered to exclude a positive effect, and, thus, the possibility that low-dose dopamine may still be beneficial could not be excluded. Therefore, the purpose of this analysis was to pool data from existing trials to evaluate the impact of dopamine on the prevention, development, and course of acute renal failure (ARF), mortality, and hemodialysis requirements in critically ill patients.
METHODS
Search Strategy. A MEDLINE search was conducted using databases of literature published from January 1966 through December 1999. Articles dealing with kidney (drug effects) and dopamine were searched. This pool of articles was then limited to clinical trials or meta-analyses of human studies. Bibliographies of original reports and review articles on these topics were also searched by hand for additional studies meeting the above criteria. This group of articles was then screened by the authors for studies addressing the use of dopamine in the prevention and/or treatment of ARF. Non-English-language articles were translated before analysis.
Inclusion and Exclusion Criteria. We included all studies in the analysis if they studied human subjects, used low-dose dopamine for the prevention and or treatment of acute renal failure, and reported primary data on at least one of the following clinical outcomes: mortality, requirement for hemodialysis, development of ARF, or worsening of existing ARF. Low-dose dopamine was defined variably across studies, always Ͻ5 g/kg/min and most often 2-4 g/kg/min. Biochemical definitions for ARF (i.e., serum creatinine concentrations) were not standardized between trials, however, criteria for ARF had to be met at least 24 hrs after discontinuation of dopamine and/or placebo. Oliguria alone was not considered sufficient for the definition of ARF. Similarly, hemodialysis was taken to be "required" if some form of renal support (including continuous renal replacement therapy and peritoneal dialysis) was used at least once for a given patient. There was no standardization of indications for hemodialysis except that they met "clinical criteria." We excluded studies if they failed to achieve any of the inclusion criteria. We did not analyze group data provided only in summary format (e.g., mean serum creatinine for the entire group).
Data Abstraction and Statistical Analysis. Both authors reviewed each study independently. The following data elements were abstracted: study design (including patient selection and randomization), population, hospital mortality, incidence and severity of ARF, and use of hemodialysis. Cumulative risk ratios (RR) were calculated for each of the primary endpoints (mortality, ARF, and hemodialysis) across individual studies using the MantelHaenszel test. All RR results are presented with the corresponding 95% confidence limits. Because only summary data were used in the analysis, a fixed effects model was applied. A p value of Ͻ.05 was considered significant. We assessed the robustness of our findings from the primary analysis to the effects of study population and baseline risk for any of the primary outcomes through a series of sensitivity analyses (5) . First, we defined two subgroups that were likely to include significantly different populations of patients based on previous reports in the literature (6, 7). The first group included patients receiving radiocontrast dye. Because the number of studies including these patients was small but the potential confounding effect was large, we recalculated cumulative RR for each outcome after excluding these studies. The group of studies excluding those with radiocontrast dye was designated as subgroup A. The second group, subgroup B, was limited to those studies enrolling patients with heart disease (either medical or surgical patients). Subgroups A and B were defined in a pre hoc fashion. Finally, subgroup C was defined post hoc and excluded studies in which the control group event rate or the effect size for each outcome was significantly different from the mean (i.e., significant outliers) as determined by analysis of variance.
We calculated power assuming an event rate in the control group of 20% and an ␣ of 0.05. We based this estimate for outcomes other than mortality on a previous review of the literature in this area (4) . For a RR of 0.5, a sample size of 438 is required to achieve an 80% power. We expected that mortality would be low and that we would not achieve sufficient sample size for this outcome.
RESULTS
A total of 58 studies were identified (n ϭ 2149 patients) ( Table 1 ). Data were reported on at least one of the four primary outcomes in 24 studies (n ϭ 1019) and the majority of these studies (17) were randomized trials (n ϭ 854). The results from the 24 studies reporting outcomes are shown in Table 2 . Because a sufficient number of randomized trials were identified, the remainder of the analysis was restricted to these studies. All statistical analysis was restricted to this group. There were no statistically significant differences between groups for any of the outcomes analyzed. Mortality was reported for 508 patients enrolled in 11 trials and was similar between treatment and control groups (4.7% vs. 5.6%; RR, 0.83 [0.39 -1.77]). Development of ARF was reported to be 15.3% in the dopamine arms and 19.5% in the control arms (RR, 0.79 [0.54 -1.13]) for 511 patients in 11 trials. Requirement for hemodialysis was reported to be 13.9% in the dopamine arms vs. 16 .5% in control arms (RR, 0.89 [0.66 -1.21]) for 618 patients in 10 studies. Worsening of existing ARF was only reported in one trial and was not analyzed further.
The results of our sensitivity analysis are reported in Figure 1 . Subgroup A (which excluded studies using radiocontrast dye) included 14 studies enrolling 661 patients. Subgroup B (heart disease only) included four studies enrolling 271 patients. Subgroup C (which excluded outliers) was composed as follows: For mortality, no studies were significantly different from the rest in terms of event rates in the control group or effect size. Thus, no studies were excluded for this outcome and there is no subgroup C result for mortality. For development of ARF, event rates in the control groups varied from 0% to 50% but were not significantly different for any one study. Effect size varied from a 20% absolute risk increase to a 33% absolute risk reduction except for one study (8) , which reported a 50% absolute risk reduction. This study was excluded from subgroup C for the development of ARF. Finally, two studies (9, 10) were excluded from subgroup C for the requirement of hemodialysis because the control group event rates (76% and 79%) were significantly different from the remainder of the trials (mean 7%, range 0% to 23%). As shown in Figure 1 , there were no differences between dopamine and control with respect to any outcome for any of the subgroups analyzed. Sufficient sample size was reached to achieve 80% power for a RR of 0.5 for two of our primary outcomes, development of ARF and requirement for dialysis. Following our analysis, we recalculated power for each of these outcomes using the actual control group event rates. For the development of ARF, we analyzed results for 511 patients with a control group event rate of 19.5%. Thus, we achieved an 85% power for a RR of 0.5 and a 65% power for a RR of 0.6. For the requirement for dialysis, we analyzed results for 618 patients with a control group event rate of 16.5%. Thus, we achieved an 85% power for a RR of 0.5 and a 60% power for a RR of 0.6.
DISCUSSION
The major finding of this study is that, despite its widespread use, there is no evidence to support the use of low-dose dopamine to prevent or treat ARF, and, therefore, dopamine should be eliminated from routine clinical use for this indication. At first glance, it is difficult to understand why low-dose dopamine does not confer any benefit to patients with, or at risk for, ARF. Low-dose dopamine is effective in increasing renal blood flow and results in increased urine output. Clinicians frequently use "renal dose" dopamine in the hopes that such a maneuver might attenuate renal injury and im- Figure 1 . Forrest plot showing relative risks (diamonds) and 95% confidence intervals (lines) for all studies and for subgroups A, B, and C. Subgroup A included 14 studies enrolling 661 patients but excluded studies using radiocontrast dye. Subgroup B was limited to heart disease and included four studies enrolling 271 patients. Subgroup C excluded statistical outliers in terms of either control group event rate or the effect size for each outcome as determined by analysis of variance. ARF, acute renal failure. prove survival. In addition, clinicians often interpret an increase in urinary output as proof that these two assumptions are valid. In reality, dopamine may increase urine output through five separate mechanisms. Dopamine stimulates both dopaminergic and adrenergic (both ␣ and ␤) receptors. As such, dopamine may affect renal blood flow by direct vasodilation (dopamine receptors), by increasing cardiac output (␤ receptors) or by increasing perfusion pressure (␣ receptors). At low doses, particularly Ͻ2g/ kg/min, the dopaminergic effects tend to predominate, although wide variability seems to exist across patients and clinical conditions. In appropriate clinical settings, any of the mechanisms might increase effective renal plasma flow and thus increase urine output. Under such conditions, the increase in urine output might well be indicative of improved renal function. However, dopamine may also increase urine output by both inhibition of aldosterone release as well as inhibition of sodium-potassium ATPase at the tubular epithelial cell level (11) . The effect of these last two mechanisms is to increase sodium excretion and thereby diuresis. Thus, apart from the direct and indirect effects on the renal vasculature, dopamine increases urine output because it is a diuretic. Much of the enthusiasm for the use of this agent comes from the belief that dopamine increases renal blood flow and that such an outcome is desirable (12) . Given that ARF in the critically ill is usually caused by acute tubular necrosis (ATN), it seems paradoxic that an agent that improves renal blood flow is not beneficial. Clearly, the continued popularity of so-called "renal dose" dopamine is the result, in large part, of this seemingly strong physiologic rationale even in the face of multiple negative clinical trials. However, a closer examination of the clinical and experimental evidence used to support the use of dopamine casts significant doubt on this underlying physiologic rationale.
First, most clinicians use so-called "renal-dose" dopamine in the belief that they can improve renal blood flow and that this will restore oxygen delivery to portions of the kidney that are dysoxic. However, it is not clear that ischemic ATN is always the result of a decrease in renal blood flow nor is it clear that increasing renal blood flow will reverse or prevent this injury. For example, one of the most common anticipated etiologies of ATN is the use of intravenous contrast agents for imaging studies. Although the pathogenesis of renal injury secondary to radiocontrast agents is not entirely understood, it seems to be due to medullary ischemia (13, 14) . For some time, it has been postulated that this ischemic injury occurs on the basis of decreased renal blood flow secondary to renal vasoconstriction. It is therefore surprising that some studies have shown that renal blood flow actually increases with radiocontrast (15) . This has lead some investigators to hypothesize that medullary ischemia is a "demand-side" problem. In other words, the ionic load leads to medullary ischemia because the medullary oxygen demand becomes greater than the supply (16, 17) . Oxygen diffuses from the descending to ascending vasa recta within vascular bundles limiting oxygen delivery to the renal medulla (17) . In addition, the medulla suffers from unusually high oxygen demand related to tubular transport activity where medullary oxygen extraction approaches 90% (18) . Thus, the renal medulla is constantly on the brink of dysoxia owing to high demand and low delivery of oxygen. Although dopamine increases outer medullary blood flow in hypovolemic animals, it fails to improve outer medullary dysoxia (19) . In fact, analogous to the situation with radiocontrast, the increased solute delivery to the distal tubular cells produced by the natriuretic effects of dopamine (via inhibition of proximal tubular resorption) might actually increase medullary oxygen consumption and thereby increase the risk of ischemia rather than decrease it (20) . This aspect of renal physiology could explain why agents that increase renal blood flow are not protective. Indeed, this scenario would predict that such agents would actually be deleterious. In fact, two recent studies (21, 22) suggest that dopamine worsens renal tubular injury secondary to radiocontrast agents (21) and in postcardiac surgery patients (22) despite an increase in renal blood flow.
Finally, drugs that oppose dopamine activity, such as metoclopramide (23) or haloperidol (24) , are not associated with any adverse renal effects despite widespread use in the same populations where "renal dose" dopamine is often advocated. Indeed, both of these agents effectively negate any the renal vascular effects of low-dose dopamine, yet neither is associated with ARF.
Thus, the existing experimental evidence does not provide conclusive support for dopamine and some studies raise concerns that dopamine may even be harmful (4, 25, 26) . These studies also call into question the appropriateness of increasing urine output in the first place. In the case of other types of diuretics, converting oliguric to nonoliguric renal failure may provide certain management advantages (e.g., controlling volume overload and hyperkalemia) but does not affect overall renal recovery or outcome (27, 28) . Accordingly, on the basis of existing evidence, the use of dopamine to improve renal function cannot be recommended. This is not to say that dopamine does not have role in the management of critically ill patients. The multiple effects of dopamine (even at low doses) may be useful in certain clinical situations. Indeed, it is a common clinical scenario in which a patient is both modestly hypotensive/vasodilated and has a degree of cardiac dysfunction. Such a patient may well benefit from the combined inotropic, vasopressor, renal vasodilator, and diuretic effects of this drug. However, as always, when safer or less invasive alternatives are available, they should be used first. For example, loop diuretics are much more effective diuretics than dopamine and are much safer. Similarly, dobutamine would be a better alternative for the patient who primarily requires an inotrope, and norepinephrine would be a better choice for a vasodilated, hyperdynamic patient. Combined norepinephrine/dobutamine therapy may also be a better option for patients requiring combination inotrope/vasopressor therapy.
Certainly, dopamine has a number of potential disadvantages. Segal et al. (29) demonstrated that low dose dopamine caused earlier onset of gut ischemia. Even at low doses, dopamine may in- crease cardiac contractility and systemic resistance, and low-dose dopamine has been reported to be associated with tissue necrosis and digital gangrene (30) , although proof of causation is lacking. Furthermore, even if dopamine were without risk, its effects can be unpredictable. This point was stressed by Flancbaum and colleagues (1) , who demonstrated that a low-dose infusion of dopamine produces a drug-dependent increase in the urinary output in oliguric, euvolemic patients in the intensive care unit and that the maximal effect is temporary and variable. Finally, given the fact that the renal effects of low-dose dopamine in patients with sepsis syndrome decrease with time, it has been suggested that there is a desensitization of renal dopaminergic and adrenergic receptors (2) . However, a notable finding of our analysis is that dopamine does not appear to increase the risk of death, ARF, or hemodialysis. Indeed, dopamine seems to be a relatively safe agent, although totally ineffective for preventing or treating renal dysfunction.
Overall, the physiologic considerations and the considerable clinical data amassed to date argue strenuously against the routine use of "renal dose" dopamine. Furthermore, with nearly 60 studies published and more than 2,000 patients enrolled, further study of this drug for the prevention or treatment of ARF should be limited to large randomized clinical trials. Additional underpowered studies should be discouraged.
